Global Helicobacter Pylori Non-invasive Testing Market to grow with 4.1% CAGR though 2027

December 06, 2019


According to the research report titled ‘Helicobacter Pylori (H. Pylori) Non-Invasive Testing Market to 2027 - Global Analysis and Forecast By Test (Serology Test, Stool Antigen Test, Urea Breath Test); Test Method (Laboratory based Tests, Point of Care Tests); End User (Hospitals, Clinics, Diagnostic Laboratories) and Geography’ available with Market Study Repot LLC, the global helicobacter pylori (H. Pylori) non-invasive testing market was worth US $539.70 million in 2018 and is estimated to grow with a CAGR of 4.1% during the period of 2019-2027, hence reaching US $768.23 million by the year 2027.
 

For the record, H. Pylori infection generally occurs during childhood and is caused by helicobacter pylori bacteria which infects the stomach. The infection can stay undetected for a long time and then result into chronic disorders including stomach cancer, peptic ulcer, and gastritis.
 

Citing an instance, World Health Organization (WHO) reported that 90% prevalence rate of H. Pylori infection is observed in emerging economies, whereas in developed countries, the disease occurence is up to 50%. The probability of infection was substantially lower in children as compared to adults, with 32.6% and 48.6% respectively.
 

Growing occurrence of H. Pylori infection among people across the globe is main factor driving the growth of helicobacter pylori non-invasive testing market for the forecast period. Development of innovative products, FDA approvals, and favorable federal initiatives promoting the importance of early and proper diagnosis are further aiding the market outlook. However, low diagnosis rates for H. Pylori infection is presumed to hinder the market growth to some extent.
 

Request sample copy of this Report@ https://www.marketstudyreport.com/request-a-sample/2202034/
 

As per test type, helicobacter pylori non-invasive testing market is categorized into stool antigen test, serology test, and urea breath test. On the basis of test method, the market is classified into point of care tests and laboratory based tests, whereas in terms of end user spectrum, the market is bifurcated into clinics, hospitals, and diagnostic laboratories.
 

Considering the geographical locations, the global H. Pylori non-invasive testing market is divided into regions namely, North America, Central & South America, Europe, Middle East & Africa, and Asia-Pacific.
 

Moreover, key players operating in H. Pylori non-invasive testing market are DiaSorin S.p.A., Thermo Fisher Scientific, Inc., Meridian Bioscience, Certest Biotec S.L., Exalenz Bioscience Ltd., Abbott, Bio-Rad Laboratories, Inc., Sekisui Diagnostics, and CorisBioconcept SPRL among others.


Frequently Asked Questions (FAQ) :

Growing occurrence of H. Pylori infection among people across the globe is the main factor driving the growth of helicobacter pylori non-invasive testing market for the forecast period. Development of innovative products, FDA approvals, and favorable federal initiatives promoting the importance of early and proper diagnosis are further aiding the market outlook.
The global helicobacter pylori (H. Pylori) non-invasive testing market was worth US $539.70 million in 2018 and is estimated to grow with a CAGR of 4.1% during the period of 2019-2027, hence reaching US $768.23 million by the year 2027.
As per test type, the helicobacter pylori non-invasive testing market is categorized into stool antigen test, serology test and urea breath test. On the basis of test method, the market is classified into point of care tests and laboratory based tests whereas in terms of end user spectrum, the market is bifurcated into clinics, hospitals and diagnostic laboratories.
The key players operating in H. Pylori non-invasive testing market are DiaSorin S.p.A., Thermo Fisher Scientific, Inc., Meridian Bioscience, Certest Biotec S.L., Exalenz Bioscience Ltd., Abbott, Bio-Rad Laboratories, Inc., Sekisui Diagnostics, and CorisBioconcept SPRL among others.